Gossamer Bio, Inc. (GOSS)
NASDAQ: GOSS · Real-Time Price · USD
9.60
+0.32 (3.39%)
Oct 13, 2026, 11:27 AM EDT - Market open
Gossamer Bio Income Statement
Financials in millions USD. Fiscal year is January - December.
Millions USD. Fiscal year is Jan - Dec.
Fiscal Year | TTM | FY 2025 | FY 2024 | FY 2023 | FY 2022 | FY 2021 |
|---|---|---|---|---|---|---|
Period Ending | Jun '26 Jun 30, 2026 | Dec '25 Dec 31, 2025 | Dec '24 Dec 31, 2024 | Dec '23 Dec 31, 2023 | Dec '22 Dec 31, 2022 | Dec '21 Dec 31, 2021 |
| 53.29 | 48.47 | 114.7 | - | - | - | |
Revenue Growth | 32.43% | -57.74% | - | - | - | - |
Gross Profit | 53.29 | 48.47 | 114.7 | - | - | - |
Selling, General & Admin | 47.94 | 37.63 | 36.13 | 38.46 | 47.61 | 45.78 |
Research & Development | 163.96 | 174.09 | 138.49 | 135.3 | 170.92 | 170.27 |
Operating Expenses | 211.9 | 211.72 | 174.62 | 173.76 | 218.53 | 216.05 |
Operating Income | -158.62 | -163.25 | -59.92 | -173.76 | -218.53 | -216.05 |
Interest Expense | -10.96 | -10.99 | -11.52 | -13.51 | -13.88 | -19.44 |
Interest & Investment Income | 1.76 | 1.97 | 1.78 | 2 | 1.58 | 0.76 |
Other Non Operating Income (Expenses) | 0.26 | 3.41 | 0.96 | 6.01 | 0.11 | 1.14 |
EBT Excluding Unusual Items | -167.56 | -168.86 | -68.7 | -179.27 | -230.72 | -233.59 |
Gain (Loss) on Sale of Investments | 7.28 | 7.28 | 13.06 | 9.45 | 1.41 | -0.34 |
Other Unusual Items | 42.45 | -1.4 | - | - | - | - |
Pretax Income | -125.31 | -170.46 | -55.64 | -179.82 | -229.38 | -234 |
Income Tax Expense | -0.09 | -0.09 | 0.89 | - | - | - |
Net Income | -125.22 | -170.37 | -56.53 | -179.82 | -229.38 | -234 |
Net Income to Common | -125.22 | -170.37 | -56.53 | -179.82 | -229.38 | -234 |
Net Income Growth | - | - | - | - | - | - |
Shares Outstanding (Basic) | 3 | 3 | 3 | 2 | 1 | 1 |
Shares Outstanding (Diluted) | 3 | 3 | 3 | 2 | 1 | 1 |
Shares Change | 11.86% | 1.01% | 48.23% | 80.46% | 13.00% | 9.24% |
EPS (Basic) | -39.49 | -59.64 | -19.99 | -94.26 | -216.97 | -250.13 |
EPS (Diluted) | -51.97 | -59.64 | -19.99 | -94.26 | -216.97 | -250.13 |
EPS Growth | - | - | - | - | - | - |
Additional Metrics
Fiscal Year | TTM | FY 2025 | FY 2024 | FY 2023 | FY 2022 | FY 2021 |
|---|---|---|---|---|---|---|
Period Ending | Jun '26 Jun 30, 2026 | Dec '25 Dec 31, 2025 | Dec '24 Dec 31, 2024 | Dec '23 Dec 31, 2023 | Dec '22 Dec 31, 2022 | Dec '21 Dec 31, 2021 |
Free Cash Flow | -162.63 | -171.35 | -3.47 | -159.16 | -187.44 | -190.44 |
Free Cash Flow Per Share | -51.29 | -59.98 | -1.23 | -83.43 | -177.30 | -203.56 |
Gross Margin | 100.00% | 100.00% | 100.00% | - | - | - |
Operating Margin | -297.67% | -336.81% | -52.24% | - | - | - |
Profit Margin | -235.00% | -351.49% | -49.28% | - | - | - |
Free Cash Flow Margin | -305.19% | -353.50% | -3.02% | - | - | - |
EBITDA | -158.6 | -163.23 | -59.09 | -172.15 | -216.7 | -214.31 |
EBITDA Margin | -297.63% | - | -51.51% | - | - | - |
D&A For EBITDA | 0.02 | 0.02 | 0.83 | 1.61 | 1.83 | 1.74 |
EBIT | -158.62 | -163.25 | -59.92 | -173.76 | -218.53 | -216.05 |
EBIT Margin | -297.67% | - | -52.24% | - | - | - |
Revenue as Reported | 53.29 | 48.47 | 114.7 | - | - | - |